Plexxikon
Berkeley · Founded 2000
About Plexxikon
Plexxikon, Inc. engages in the discovery and development of small molecule pharmaceuticals to treat human disease. The company's products include PLX204 for the treatment of diabetes; PLX4032 for the treatment of melanoma and colorectal cancer; and PLX5568 kinase inhibitors for the treatment of pain, polycystic kidney disease, rheumatoid arthritis, metastatic breast cancer, and renal disease. It develops a portfolio of clinical and preclinical stage programs in various therapeutic areas, including metabolic disease, such as obesity indications; oncology, such as osteolytic metastatic disease; and CNS, such as multiple sclerosis. The company’s portfolio of clinical and preclinical stage programs for other therapeutic areas include inflammation, such as systemic lupus erythematosus, inflammatory bowel disease, and osteoporosis; and cardiovascular, including hypertension and atherosclerosis.
Company Facts
- Founded: 2000
- Legal name: Plexxikon, Inc.
- Operating status: Acquired
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $80.3M
- Funding stage: M&A
- Last round: Series B (Mar 2005)
- Website: plexxikon.com
- Phone: (510)548-8014
Social Profiles
Canonical: https://fsome.com/organization/plexxikon-8339293 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.